The beta-2-glycoprotein I antibody is one of three primary antiphospholipid antibodies, which are autoantibodies that target the body’s own lipid-proteins and phospholipids found in the cell membranes and platelets. It is less common than cardiolipin antibodies and lupus anticoagulant.
Antiphospholipid antibodies interfere with the body’s blood clotting process. They frequently appear in patients with antiphospholipid syndrome (APS), an autoimmune disease associated with thrombotic episodes, thrombocytopenia, or pregnancy complications. One or more antiphospholipid antibodies may also be seen with other autoimmune disorders, such as systemic lupus erythematosus (SLE).
Beta-2-glycoprotein I antibody is less common than the other antiphospholipid antibodies; however, beta-2-glycoprotein I antibodies have been reported to be more specific than cardiolipin antibodies for the diagnosis of APS.
Tests for beta-2-glycoprotein I have to be performed repeatedly after a period of about 12 weeks to confirm that the patient has a permanent antibody status that is prerequisite for the diagnosis of APS.
Antibodies to beta-2-glycoprotein I can be measured with ELISA tests, either as a single antigen test or in combination with other phospholipids.
Tests offered by ORGENTEC Diagnostika
Anti-beta-2-Glycoprotein I IgG/IgM (ORG 521, ORG 221G, ORG 221M)
Anti-beta-2 Glycoprotein I IgA (ORG 521A, ORG 221A)
Anti-beta-2 glycoprotein I Screen (ORG 521S, ORG 221S)
Anti-Phospholipid Screen (ORG 529, ORG 229G, ORG 229M)